AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Research
The volume and pace of cancer research, from preclinical studies to clinical trials and FDA approvals, can make it challenging to stay informed. This section highlights the latest developments and translates complex scientific concepts into clear, accessible insights for both healthcare professionals and the broader public.
Recognizing and Treating Triple M Syndrome: A Checkpoint Inhibitor Toxicity Case
By Katherine Hill, PharmD, BCOP
Triple M syndrome, the co-occurrence of myocarditis, myasthenia gravis, and myositis, is a rare but potentially fatal complication of immune checkpoint inhibitor (ICI) therapy, with reported fatality rates approaching 30-50%.
Recognizing and Treating Triple M Syndrome: A Checkpoint Inhibitor Toxicity Case
By Katherine Hill, PharmD, BCOP
Triple M syndrome, the co-occurrence of myocarditis, myasthenia gravis, and myositis, is a rare but potentially fatal complication of immune checkpoint inhibitor (ICI) therapy, with reported fatality rates approaching 30-50%.
Recognizing and Treating Triple M Syndrome: A Checkpoint Inhibitor Toxicity Case
By Katherine Hill, PharmD, BCOP
Triple M syndrome, the co-occurrence of myocarditis, myasthenia gravis, and myositis, is a rare but potentially fatal complication of immune checkpoint inhibitor (ICI) therapy, with reported fatality rates approaching 30-50%.
Hormone Receptor-Positive Breast Cancer in 2026: Navigating a More Complex Treatment Landscape
By Christos Vaklavas, MD
The treatment algorithm for hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer has grown substantially more complex over the past several years
Hormone Receptor-Positive Breast Cancer in 2026: Navigating a More Complex Treatment Landscape
By Christos Vaklavas, MD
The treatment algorithm for hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer has grown substantially more complex over the past several years
Hormone Receptor-Positive Breast Cancer in 2026: Navigating a More Complex Treatment Landscape
By Christos Vaklavas, MD
The treatment algorithm for hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer has grown substantially more complex over the past several years
Adjuvant Immunotherapy Keeps Falling Short in Early Lung Cancer, So the Field Is Moving the Timeline Up
By Balazs Halmos, MD
Lung cancer remains the leading cause of cancer death worldwide, though the trajectory has shifted meaningfully: lung cancer mortality in the United States has fallen by roughly half over the past 25 years.
Adjuvant Immunotherapy Keeps Falling Short in Early Lung Cancer, So the Field Is Moving the Timeline Up
By Balazs Halmos, MD
Lung cancer remains the leading cause of cancer death worldwide, though the trajectory has shifted meaningfully: lung cancer mortality in the United States has fallen by roughly half over the past 25 years.
Adjuvant Immunotherapy Keeps Falling Short in Early Lung Cancer, So the Field Is Moving the Timeline Up
By Balazs Halmos, MD
Lung cancer remains the leading cause of cancer death worldwide, though the trajectory has shifted meaningfully: lung cancer mortality in the United States has fallen by roughly half over the past 25 years.
Managing Enfortumab Vedotin-Induced Peripheral Neuropathy: A Practical Case Review
By Alexandra Koehler, DNP
Enfortumab vedotin plus pembrolizumab (EV+P) has transformed frontline treatment for metastatic urothelial carcinoma, roughly doubling median overall survival compared with platinum-based chemotherapy in the EV-302 trial.
Managing Enfortumab Vedotin-Induced Peripheral Neuropathy: A Practical Case Review
By Alexandra Koehler, DNP
Enfortumab vedotin plus pembrolizumab (EV+P) has transformed frontline treatment for metastatic urothelial carcinoma, roughly doubling median overall survival compared with platinum-based chemotherapy in the EV-302 trial.
Managing Enfortumab Vedotin-Induced Peripheral Neuropathy: A Practical Case Review
By Alexandra Koehler, DNP
Enfortumab vedotin plus pembrolizumab (EV+P) has transformed frontline treatment for metastatic urothelial carcinoma, roughly doubling median overall survival compared with platinum-based chemotherapy in the EV-302 trial.
RASolute 302: A Turning Point for RAS-Targeted Therapy in Pancreatic Cancer
By Brandon G. Smaglo, MD
The 2026 ASCO Annual Meeting brought what may be the most significant pancreatic cancer data in years:
RASolute 302: A Turning Point for RAS-Targeted Therapy in Pancreatic Cancer
By Brandon G. Smaglo, MD
The 2026 ASCO Annual Meeting brought what may be the most significant pancreatic cancer data in years:
RASolute 302: A Turning Point for RAS-Targeted Therapy in Pancreatic Cancer
By Brandon G. Smaglo, MD
The 2026 ASCO Annual Meeting brought what may be the most significant pancreatic cancer data in years:
Practical Updates in Cervical, Ovarian, and Endometrial Cancer From ASCO 2026
By Andrew Emmons Green, MD
Not every practice-relevant finding from the 2026 ASCO Annual Meeting comes from a single blockbuster trial.
Practical Updates in Cervical, Ovarian, and Endometrial Cancer From ASCO 2026
By Andrew Emmons Green, MD
Not every practice-relevant finding from the 2026 ASCO Annual Meeting comes from a single blockbuster trial.
Practical Updates in Cervical, Ovarian, and Endometrial Cancer From ASCO 2026
By Andrew Emmons Green, MD
Not every practice-relevant finding from the 2026 ASCO Annual Meeting comes from a single blockbuster trial.
Monitoring for Interstitial Lung Disease With Trastuzumab Deruxtecan: A Practice-Changing Case
By Erica Doubleday, NP
Antibody-drug conjugates (ADCs) combine the precision of targeted therapy with the cell-killing power of chemotherapy, and few have been more transformative in breast cancer than fam-trastuzumab deruxtecan (T-DXd)
Monitoring for Interstitial Lung Disease With Trastuzumab Deruxtecan: A Practice-Changing Case
By Erica Doubleday, NP
Antibody-drug conjugates (ADCs) combine the precision of targeted therapy with the cell-killing power of chemotherapy, and few have been more transformative in breast cancer than fam-trastuzumab deruxtecan (T-DXd)
Monitoring for Interstitial Lung Disease With Trastuzumab Deruxtecan: A Practice-Changing Case
By Erica Doubleday, NP
Antibody-drug conjugates (ADCs) combine the precision of targeted therapy with the cell-killing power of chemotherapy, and few have been more transformative in breast cancer than fam-trastuzumab deruxtecan (T-DXd)
Precision Over Protocol: What's New in HR-Positive, HER2-Negative Breast Cancer
By Sasha Stanton, MD, PhD
Hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer is the most common subtype of breast cancer and its treatment landscape has never been more complex or more promising.
Precision Over Protocol: What's New in HR-Positive, HER2-Negative Breast Cancer
By Sasha Stanton, MD, PhD
Hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer is the most common subtype of breast cancer and its treatment landscape has never been more complex or more promising.
Precision Over Protocol: What's New in HR-Positive, HER2-Negative Breast Cancer
By Sasha Stanton, MD, PhD
Hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer is the most common subtype of breast cancer and its treatment landscape has never been more complex or more promising.
CAR-T Cell Therapy for Relapsed Aggressive Lymphoma: Who to Refer, When, and What's Coming Next
By Paul Shaughnessy, MD
Before CAR-T cell therapy existed, patients with chemotherapy-refractory diffuse large B-cell lymphoma had a median overall survival of 6.3 months, a complete response rate of 7%, and only 20% alive at two years.
CAR-T Cell Therapy for Relapsed Aggressive Lymphoma: Who to Refer, When, and What's Coming Next
By Paul Shaughnessy, MD
Before CAR-T cell therapy existed, patients with chemotherapy-refractory diffuse large B-cell lymphoma had a median overall survival of 6.3 months, a complete response rate of 7%, and only 20% alive at two years.
CAR-T Cell Therapy for Relapsed Aggressive Lymphoma: Who to Refer, When, and What's Coming Next
By Paul Shaughnessy, MD
Before CAR-T cell therapy existed, patients with chemotherapy-refractory diffuse large B-cell lymphoma had a median overall survival of 6.3 months, a complete response rate of 7%, and only 20% alive at two years.
Small Cell Lung Cancer in 2026: Tarlatamab Changes the Arc, and a New Wave of ADCs Is Coming
By Rafael Santana-Davila, MD
Tarlatamab has changed the arc of small cell lung cancer — the first treatment in years to improve survival in the second-line setting. Dr. Rafael Santana-Davila maps the 2026 landscape and the ADC wave that's coming.
Small Cell Lung Cancer in 2026: Tarlatamab Changes the Arc, and a New Wave of ADCs Is Coming
By Rafael Santana-Davila, MD
Tarlatamab has changed the arc of small cell lung cancer — the first treatment in years to improve survival in the second-line setting. Dr. Rafael Santana-Davila maps the 2026 landscape and the ADC wave that's coming.
Small Cell Lung Cancer in 2026: Tarlatamab Changes the Arc, and a New Wave of ADCs Is Coming
By Rafael Santana-Davila, MD
Tarlatamab has changed the arc of small cell lung cancer — the first treatment in years to improve survival in the second-line setting. Dr. Rafael Santana-Davila maps the 2026 landscape and the ADC wave that's coming.